{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-172277","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2024-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.474672+00:00","generated_at":"2026-06-01T00:38:48.777763+00:00","sec_items":["1.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Verrica amends credit agreement with OrbiMed; revenue test deferred to Sept 30, 2024","bullets":["Amendment to Credit Agreement moves revenue test start from earlier date to September 30, 2024.","$500,000 amendment fee paid to lenders in connection with the amendment.","Revenue test determines if principal payments (including premium) are required based on YCANTH net revenue.","No other terms of the Credit Agreement were changed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-172277","json":"https://secwatch.observer/filing/0001193125-24-172277.json","markdown":"https://secwatch.observer/filing/0001193125-24-172277.md","text":"https://secwatch.observer/filing/0001193125-24-172277.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524172277/0001193125-24-172277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312524172277/d844833d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T00:38:48.777763+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}